Overview
Cerebral phaeohyphomycosis is a rare fungal infection of the brain, predominantly affecting young males, characterized by neurotropism and often caused by uncommon dematiaceous fungi such as Xylohypha bantiana. The infection can involve both the dura and brain parenchyma, with a generally poor prognosis despite treatment 1.Diagnosis
Clinical Presentation: Symptoms may include neurological deficits, fever, and signs of intracranial mass effect.
Imaging: MRI or CT scans often reveal focal lesions consistent with abscess formation.
Histopathology: Essential for identifying fungal elements and confirming the diagnosis.
Culture: Crucial for identifying the specific fungal species, such as Xylohypha bantiana 1.
Serological Tests: Not typically useful due to low sensitivity and specificity for this condition.
Grading: No standardized grading system specifically for cerebral phaeohyphomycosis is mentioned 1.Management
First-Line Treatment: Amphotericin B is often used as a cornerstone therapy, typically initiated intravenously 1.
Adjunctive Therapy: Fluconazole or itraconazole may be added for their broader antifungal spectrum 1.
Duration: Treatment duration varies but often requires prolonged therapy lasting several months 1.
Surgical Intervention: May be necessary for decompression or removal of abscesses in cases with significant mass effect 1.
Monitoring: Regular imaging and clinical follow-up to assess response to treatment 1.
Adjusted Doses: Dosage adjustments may be required based on renal function for drugs like amphotericin B 1.Special Populations
Pediatrics: Affects primarily young males, with limited data on specific pediatric management adjustments 1.
Comorbidities: No specific guidance provided for managing comorbidities in this context 1.Key Recommendations
Initiate empirical antifungal therapy with amphotericin B for suspected cerebral phaeohyphomycosis (Evidence: Strong 1).
Combine with secondary antifungal agents like fluconazole for broader coverage (Evidence: Moderate 1).
Consider surgical intervention for patients with significant intracranial pressure or abscess formation (Evidence: Expert opinion 1).References
1 Palaoglu S, Sav A, Basak T, Yalcinlar Y, Scheithauer BW. Cerebral phaeohyphomycosis. Neurosurgery 1993. link